CTOs on the Move

Zucara Therapeutics

www.zucara.ca

 
Zucara Therapeutics, a CDRD and MaRS Innovation portfolio company, is developing the first drug therapy to prevent hypoglycemia in people with diabetes. Our first-in-class therapeutic is focused on improving glucagon counterregulation by inhibiting somatostatin which is dysregulated in Type 1 diabetes.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.zucara.ca
  • 4th Floor 2405 Wesbrook Mall
    Vancouver, BC CAN V6T 1Z3
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Zucara Therapeutics raised $21M on 03/31/2020

Similar Companies

Comp-U-charge

Comp-U-charge is a Spokane, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AiVita Biomedical

AIVITA Biomedical is a privately held company engaged in the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines.

Bellus Health

BELLUS Health is a clinical stage biotechnology company developing novel therapeutics for the treatment of chronic cough and other chronic disorders triggered by hypersensitization.

Magnolia NeuroSciences

Magnolia Neurosciences Corporation is a drug discovery and development company focused on the creation of a novel class of neuroprotective medicines.

Rapid Pathogen Screening

Founded in 2004, Rapid Pathogen Screening is an emerging developer, manufacturer, and marketer of rapid point-of-care (POC) diagnostic tests. The company’s innovative and patented technology platform facilitates the development of a spectrum of cost-effective tests to rapidly identify patients with infectious diseases and inflammatory conditions. As a result of U.S. government contracts, this platform is also being used to develop tests for bio-terrorism and chemical nerve agent blood toxins. RPS tests have high sensitivity and specificity, and can be easily performed by a clinician or their staff without extensive training or additional equipment.